These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45 related articles for article (PubMed ID: 8587420)
21. Action and binding of the endothelin antagonist bosentan on astrocytes of cultured rat central nervous system. Electrophysiological and autoradiographic studies. Hösli E; Pauli C; Ledergerber M; Stauffer S; Hösli L Regul Pept; 1996 Oct; 66(3):149-53. PubMed ID: 8916269 [TBL] [Abstract][Full Text] [Related]
22. [125I]-endothelin-1 binding to vasa vasorum and regions of neovascularization in human and porcine blood vessels: a possible role for endothelin in intimal hyperplasia and atherosclerosis. Dashwood MR; Barker SG; Muddle JR; Yacoub MH; Martin JF J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S343-7. PubMed ID: 7509983 [TBL] [Abstract][Full Text] [Related]
23. Endothelin-1 displaces [3H]nicardipine binding in sections of human renal artery. Amenta F; Ferrante F J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S171-3. PubMed ID: 7509935 [TBL] [Abstract][Full Text] [Related]
24. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Muenter K; Dashwood MR Hypertension; 2001 May; 37(5):E13. PubMed ID: 11358955 [No Abstract] [Full Text] [Related]
25. Autoradiographic localisation of endothelin binding sites in human and porcine coronary arteries. Power RF; Wharton J; Salas SP; Kanse S; Ghatei M; Bloom SR; Polak JM Eur J Pharmacol; 1989 Jan; 160(1):199-200. PubMed ID: 2540992 [No Abstract] [Full Text] [Related]
28. [Endothelin-1 in coronary artery disease]. Myszka W; Kara-Perz H; Torliński L Pol Merkur Lekarski; 2001 Oct; 11(64):291-4. PubMed ID: 11770304 [TBL] [Abstract][Full Text] [Related]
29. Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan. Antoniu SA Expert Opin Ther Targets; 2008 Sep; 12(9):1077-84. PubMed ID: 18694375 [TBL] [Abstract][Full Text] [Related]
30. [3H]bosentan binding to human coronary artery: functional correlates. Dashwood MR; Timm M; Muddle JR; Shah D; Tippins JR; Kaski JC J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S376-9. PubMed ID: 8587420 [TBL] [Abstract][Full Text] [Related]
31. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Wang QD; Li XS; Lundberg JM; Pernow J Cardiovasc Res; 1995 Jun; 29(6):805-12. PubMed ID: 7656284 [TBL] [Abstract][Full Text] [Related]
32. Distribution of endothelin receptors in atherosclerotic human coronary arteries. Bacon CR; Cary NR; Davenport AP J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S439-41. PubMed ID: 8587438 [TBL] [Abstract][Full Text] [Related]
33. Regional variations in ETA/ETB binding sites in human coronary vasculature. Dashwood MR; Timm M; Kaski JC J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S351-4. PubMed ID: 8587412 [TBL] [Abstract][Full Text] [Related]
34. Endothelin receptor subtypes and their functional relevance in human small coronary arteries. Pierre LN; Davenport AP Br J Pharmacol; 1998 Jun; 124(3):499-506. PubMed ID: 9647474 [TBL] [Abstract][Full Text] [Related]
35. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. Clozel M; Breu V; Gray GA; Kalina B; Löffler BM; Burri K; Cassal JM; Hirth G; Müller M; Neidhart W J Pharmacol Exp Ther; 1994 Jul; 270(1):228-35. PubMed ID: 8035319 [TBL] [Abstract][Full Text] [Related]